Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v3.20.2
Summary of significant accounting policies (Tables)
 12 Months Ended
Jul. 31, 2020
Accounting Policies [Abstract]  
Schedule of net accounts receivable by segment
    July 31, 2020     July 31, 2019  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                        
Third party payers   $ 2,455       40     $ 2,956       44  
Patient self-pay     2,044       33       2,360       35  
Medicare     884       14       910       13  
HMO’s     797       13       574       8  
Total Clinical Labs     6,180       100 %     6,800       100 %
Total Life Sciences     2,961               3,938          
Total accounts receivable – net   $ 9,141             $ 10,738          
Schedule of basic and diluted net income (loss) per share
    2020     2019     2018  
Net (loss) income   $ (28,520 )   $ 2,489     $ (10,321 )
                         
Weighted-average common shares outstanding - basic     47,696       47,351       46,972  
Add: effect of dilutive stock options and restricted stock     —       125       —  
Weighted-average common shares outstanding - diluted     47,696       47,476       46,972  
                         
Net (loss) income per share – basic   $ (0.60 )   $ 0.05     $ (0.22 )
Net (loss) income per share – diluted   $ (0.60 )   $ 0.05     $ (0.22 )
Schedule of expense related to share-based payment arrangements
    2020     2019     2018  
Cost of clinical laboratory services   $ 46     $ —     $ —  
Selling, general and administrative     887       939       813  
    $ 933     $ 939     $ 813  
Schedule of adoption of the standard on prior period consolidated operations, cash flows and balance sheet
Consolidated Statements of Operations for fiscal year ended July 31, 2018:   As Previously Reported     Adjustment for New Accounting Standard on Revenue Recognition     Reclassification of Residual     As Restated  
Total Revenues   $ 104,713     ($ 3,700 )     —     $ 101,013  
Provision for uncollectible accounts receivable     3,690       (3,700 )   $ 10       —  
Selling, general and administrative expenses     44,465       —       (10 )     44,455  
Net loss     (10,321 )     —       —       (10,321 )
Consolidated Statements of Cash Flows July 31, 2018:   As Previously Reported     Adjustment for New Accounting Standard on Revenue Recognition    

 

Reclassification of Residual

    

 

As Restated

  
Provision for uncollectible accounts receivable     3,690       (3,700 )     10       —  
Changes in operating assets and liabilities: Accounts receivable     (1,775 )     3,700       (10 )     1,915  
Consolidated balance sheet July 31, 2018:                                
Accounts receivable     15,815       (2,523 )     —       13,292  
Less: Allowance for doubtful accounts     2,668       (2,523 )          —       145  
Accounts receivable, net of allowance for doubtful accounts     13,147       —       —       13,147